<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03766659</url>
  </required_header>
  <id_info>
    <org_study_id>MORE</org_study_id>
    <nct_id>NCT03766659</nct_id>
  </id_info>
  <brief_title>EUS-FNB With MOSE vs EUS-FNA With ROSE</brief_title>
  <acronym>MORE</acronym>
  <official_title>Endoscopic Ultrasound-guided Fine Needle Biopsy With Macroscopic On-Site Evaluation vs Fine Needle Aspiration With Rapid On-Site Evaluation for Solid Pancreatic Lesions: A Multi-centered Prospective Randomized Controlled Trial (MORE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is an indispensable tool for
      tissue acquisition for pancreatic lesions. However, FNA alone has several limitations
      including inadequate acquisition of cells, and unable to provide core tissue for further
      histological analysis. The use of rapid on-site evaluation (ROSE) by cytopathologist has the
      biggest impact on improving diagnostic accuracy and is regarded as the gold standard for
      EUS-FNA. Unfortunately, it is not widely available due to limited resources.

      In order to overcome these limitations, new fine needle biopsy (FNB) needles have been
      recently developed to collect not only cells but also the entire core tissue for histological
      analysis. Having core biopsy with preserved tissue provides additional advantages of allowing
      molecular analysis, which are of emerging importance in cancer management. Early results
      comparing FNB with FNA showed the superiority of FNB over FNA in the absence of ROSE. Data
      comparing FNB and FNA with ROSE are limited. In order to study to true merits of FNB over
      FNA, comparison with the most optimal method is necessary.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the diagnostic yield of EUS-FNB with MOSE vs EUS-FNA
      with ROSE.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>International multicenter prospective randomized comparative study.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic yield</measure>
    <time_frame>1 month after Procedure</time_frame>
    <description>the proportion of patients with adequate tissue for diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morbidity rate</measure>
    <time_frame>1 month after Procedure</time_frame>
    <description>Procedure-related morbidity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>MOSE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>EUS-FNB with MOSE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROSE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>EUS-FNA with ROSE</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MOSE</intervention_name>
    <description>EUS-FNB with MOSE</description>
    <arm_group_label>MOSE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ROSE</intervention_name>
    <description>EUS-FNA with ROSE</description>
    <arm_group_label>ROSE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 80 years

          -  Referred for EUS-guided tissue acquisition of solid pancreatic lesions greater than
             1cm in the largest diameter

        Exclusion Criteria:

          -  Coagulopathy

          -  Altered anatomy

          -  Contraindications for conscious sedation

          -  Pregnancy

          -  Those who cannot provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charing CHONG</last_name>
    <phone>3505 3933</phone>
    <email>chongcn@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philip Yeung</last_name>
    <phone>3404 3933</phone>
    <email>philipyeung@surgery.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Surgery; The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charing C Chong, MBChB</last_name>
      <phone>852-26321496</phone>
      <email>Chongcn@surgery.cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Charing C Chong, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Charing Chong, MD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

